Nurix Therapeutics, Inc. (NRIX)
22.16
-0.19
(-0.85%)
USD |
NASDAQ |
Oct 12, 16:00
22.55
+0.39
(+1.76%)
After-Hours: 04:45
Nurix Therapeutics Enterprise Value : 1.315B for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 1.315B |
| October 09, 2026 | 1.335B |
| October 08, 2026 | 1.320B |
| October 07, 2026 | 1.374B |
| October 06, 2026 | 1.361B |
| October 05, 2026 | 1.390B |
| October 02, 2026 | 1.401B |
| October 01, 2026 | 1.437B |
| September 30, 2026 | 1.476B |
| September 29, 2026 | 1.472B |
| September 28, 2026 | 1.472B |
| September 25, 2026 | 1.403B |
| September 24, 2026 | 1.470B |
| September 23, 2026 | 1.493B |
| September 22, 2026 | 1.679B |
| September 21, 2026 | 1.652B |
| September 18, 2026 | 1.655B |
| September 17, 2026 | 1.661B |
| September 16, 2026 | 1.625B |
| September 15, 2026 | 1.592B |
| September 14, 2026 | 1.664B |
| September 11, 2026 | 1.620B |
| September 10, 2026 | 1.694B |
| September 09, 2026 | 1.740B |
| September 08, 2026 | 1.727B |
| Date | Value |
|---|---|
| September 04, 2026 | 1.728B |
| September 03, 2026 | 1.643B |
| September 02, 2026 | 1.695B |
| September 01, 2026 | 1.717B |
| August 31, 2026 | 1.691B |
| August 28, 2026 | 2.333B |
| August 27, 2026 | 2.402B |
| August 26, 2026 | 2.384B |
| August 25, 2026 | 2.409B |
| August 24, 2026 | 2.339B |
| August 21, 2026 | 2.386B |
| August 20, 2026 | 2.420B |
| August 19, 2026 | 2.496B |
| August 18, 2026 | 2.407B |
| August 17, 2026 | 2.432B |
| August 14, 2026 | 2.420B |
| August 13, 2026 | 2.434B |
| August 12, 2026 | 2.376B |
| August 11, 2026 | 2.307B |
| August 10, 2026 | 2.298B |
| August 07, 2026 | 2.262B |
| August 06, 2026 | 2.230B |
| August 05, 2026 | 2.220B |
| August 04, 2026 | 2.175B |
| August 03, 2026 | 2.023B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 207.96B |
| ACADIA Pharmaceuticals, Inc. | 2.458B |
| Alnylam Pharmaceuticals, Inc. | 30.04B |
| Anika Therapeutics, Inc. | 260.79M |
| Savara, Inc. | 851.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 549.81M |
| Revenue (Quarterly) | 673.06M |
| Total Expenses (Quarterly) | 123.26M |
| EPS Diluted (Quarterly) | 4.73 |
| Profit Margin (Quarterly) | 81.69% |
| Earnings Yield | 10.42% |
| Operating Earnings Yield | 12.09% |